Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in atopic dermatitis (ECZTEND)
NCT03587805Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2018
- Primary completion
- Jul 2024
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoint: Number of Adverse Events at 268 weeks. Started Mar 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03587805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587805.